To determine whether immunosuppressive TAMs are more predominant in BRCA1-deficient breast cancers than in ovarian cancers, we compared treatment-naïve mouse breast and ovarian BRCA1-deficient tumors. This evidence concerns the gene BRCA1 and ovarian carcinoma.